NPPB and Huntington disease: To further explore which variables could be independently associated with BNP levels, we assessed correlations between changes in BNP and clinical variables and acylcarnitine ratios, such as (C16 + C18:1)/C2, a marker of CPT2 deficiency; C0/(C16 + C18), a marker of CPT1 deficiency; C8/C10, a marker of medium-chain acyl-CoA dehydrogenase deficiency; and C14/C3, another marker of CPT2 deficiency, by univariate and multiple regression analyses in all HD patients.